Source comparison
Tesamorelin + Ipamorelin vs Other Peptide Combinations: Research Comparison
Before selecting a peptide protocol, understanding how different combinations perform in controlled research settings provides critical context for study design. Tesamorelin + Ipamorelin Dual-pathway GH release (GHRH + ghrelin receptor) +40–60% at 8 weeks 60%
This comparison does not assign a generated winner or score.
- Before selecting a peptide protocol, understanding how different combinations perform in controlled research settings provides critical context for study design.
- Tesamorelin + Ipamorelin
- Dual-pathway GH release (GHRH + ghrelin receptor)
- +40–60% at 8 weeks
- 60% reduction in lean mass loss vs control
- 15–18% reduction over 26 weeks
- Best-evidenced combination for body recomposition research. Synergistic receptor activation produces higher GH pulses than either compound alone
- CJC-1295 + Ipamorelin
- Extended GHRH analog + ghrelin receptor agonist
- +35–50% at 8 weeks
- 50% reduction in lean mass loss vs control
- 10–12% reduction over 26 weeks
- Comparable efficacy to tesamorelin blend but longer half-life allows once-daily dosing. Trade-off is higher incidence of water retention
- MK-677 (Ibutamoren) Monotherapy
- Oral ghrelin receptor agonist
- +30–45% at 8 weeks
- 40% reduction in lean mass loss vs control
- 8–10% reduction over 26 weeks
- Convenient oral administration but less precise GH pulse control. Appetite stimulation (via ghrelin pathway) complicates fat loss protocols
- GHRP-6 + Mod GRF 1-29
- First-generation ghrelin agonist + GHRH analog
- +25–40% at 8 weeks
- 45% reduction in lean mass loss vs control
- 8–12% reduction over 26 weeks
- Lower cost but higher side effect incidence (cortisol elevation, prolactin spike). Less favourable for long-duration studies